30 completed, 12 recruiting, 10 active not recruiting, 8 terminated. 45 Phase 2, 26 Phase 1, 5 Phase 3, 2 Not applicable, 1 Phase 4.
Follow CPX-351: new trials by email Literature Review of CPX-351 trials Research Report on CPX-351
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) Bortezomib, CPX-351 - Acute Myeloid Leukemia, TP53 | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 32 | 2025-07-07 | 2026-07-22 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Cytarabine, Venetoclax, CPX-351 - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Eastern Cooperative Oncology Group | 184 | 2024-10-23 | 2024-07-03 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-21 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-21 |
| Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS Magrolimab, 7+3, CPX-351 - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Withdrawn | Uwe Platzbecker | 2024-03-31 | 2024-02-12 | |
| VYxeoS Liposomal Italian Observational Study iN the Real Practice Vyxeos liposomal - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Completed | Jazz Pharmaceuticals | 113 | 2023-12-07 | 2025-11-20 | |
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection (cytarabine: daunorubicin) liposome for injection, Vyxeos - Acute Myeloid Leukemia | Not applicable | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 36 | 2023-08-25 | 2023-09-21 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Phase IB/II of CPX-351 for Relapse Prevention in AML CPX-351 - Acute Myeloid Leukemia (AML) in Remission | Phase 1 / Phase 2 | Recruiting | Georgetown University | 24 | 2023-05-22 | 2026-03-23 |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Vyxeos, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2023-02-16 | 2026-02-27 |
| Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms CPX-351, MHA, Allogeneic Hematopoietic Stem Cell Transplantation - Myeloid Neoplasm | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 25 | 2023-01-17 | 2026-10-15 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| Vyxeos for Induction of Low- or Intermediate-risk. Vyxeos, Mylotarg - Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | Shaare Zedek Medical Center | 20 | 2022-08-07 | 2026-10-08 |
| Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia CPX-351, Midostaurin, Busulfan - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Guenther Koehne | 2022-07-05 | 2024-10-01 | |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm CPX-351 - Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | Completed | French Innovative Leukemia Organisation | 42 | 2022-03-23 | 2024-10-29 |
| CPX-351 Real-World Effectiveness and Safety Study CPX-351 - Acute Myeloid Leukemia | Completed | Jazz Pharmaceuticals | 147 | 2022-01-14 | 2022-07-12 | |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myeloid, Acute (56) · Myelodysplastic Syndromes (17) · Leukemia (8) · Myeloproliferative Disorders (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Recurrence (4) · Burkitt Lymphoma (3) · Leukemia, Monocytic, Acute (3) · Leukemia, Myelomonocytic, Chronic (3) · Hematologic Neoplasms (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Congenital Abnormalities (1)
Jazz Pharmaceuticals (13) · M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (4) · Weill Medical College of Cornell University (4) · Children's Oncology Group (3) · Fred Hutchinson Cancer Center (3) · Case Comprehensive Cancer Center (2) · Children's Hospital Medical Center, Cincinnati (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Jonsson Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Cardiff University (1) · Eastern Cooperative Oncology Group (1) · French Innovative Leukemia Organisation (1)
United States (55) · Canada (8) · France (3) · Puerto Rico (3) · United Kingdom (3) · Austria (2) · Germany (2) · Australia (1) · China (1) · Denmark (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1)
Sudipto Mukherjee, MD, PhD (3) · Caspian Oliai, MD (2) · Ellen K Ritchie, MD (2) · John Perentesis, MD (2) · Roland Walter (2) · Todd M Cooper (2) · Arthur Louie, M.D. (1) · Bijal Shah, M.D. (1) · Branko Cuglievan (1) · Charles Craddock, Professor (1) · Chezi Ganzel, DR (1) · Courtney DiNardo, MD (1) · Deepa Jeyakumar, MD (1)
PMID 33208914, PMID 22840315, PMID 24687088, PMID 26660428, PMID 30024784, PMID 31098682, PMID 31760835, PMID 32102577, PMID 32401633, PMID 33724305, PMID 33843815, PMID 34171279, PMID 34256819, PMID 35450817, PMID 36289532, PMID 36902217, PMID 37245522, PMID 37946611, PMID 38000343, PMID 38107263, PMID 38473278, PMID 38947228, PMID 39418644, PMID 39476204, PMID 40298352, PMID 40401707, PMID 40932876, PMID 40990091, PMID 41237344, PMID 41628350, PMID 42497367, PMID 42559085, PMID 42835577
U10CA180886 (3), U10CA180888 (2), 2018 (1), P30CA015704 (1), P30CA036727 (1), P30CA124435 (1), U10CA180820 (1), UM1CA186712 (1)